Nonalcoholic fatty liver disease (NAFLD) is an increasingly prevalent liver pathology characterized by hepatic steatosis and commonly accompanied by systematic inflammation and metabolic disorder. Despite an accumulating number of studies, no pharmacological strategy is available to treat this condition in the clinic. In this study, we applied extensive gainand loss-of-function approaches to identify the key immune factor leukocyte immunoglobulin-like receptor B4 (LILRB4) as a negative regulator of NAFLD. The hepatocyte-specific knockout of LILRB4 (LILRB4-HKO) exacerbated high-fat diet-induced insulin resistance, glucose metabolic imbalance, hepatic lipid accumulation, and systematic inflammation in mice, whereas LILRB4 overexpression in hepatocytes showed a completely opposite phenotype relative to that of LILRB4-HKO mice when compared with their corresponding controls. Further investigations of molecular mechanisms demonstrated that LILRB4 recruits SHP1 to inhibit TRAF6 ubiquitination and subsequent inactivation of nuclear factor kappa B and mitogen-activated protein kinase cascades. From a therapeutic perspective, the overexpression of LILRB4 in a genetic model of NAFLD, ob/ob mice, largely reversed the inherent hepatic steatosis, inflammation, and metabolic disorder. Conclusion: Targeting hepatic LILRB4 to improve its expression or activation represents a promising strategy for the treatment of NAFLD as well as related liver and metabolic diseases. (HEPATOLOGY 2018;67:1303-1319 
N onalcoholic fatty liver disease (NAFLD), characterized by lipid accumulation in the liver, is a global epidemic with a morbidity of up to 20%-40% worldwide.
(1) The occurrence of NAFLD predisposes patients to severe liver diseases, including nonalcoholic steatohepatitis (NASH), liver cirrhosis, and hepatocellular carcinoma, and it is commonly accompanied by metabolic disorders such as obesity, insulin resistance, and hyperglycemia. (2, 3) However, no evidence-based pharmacological approach is clinically available to treat NAFLD. (4) Therefore, the identification of effective targets and the Abbreviations: ALT, alanine aminotransferase; AST, aspartate aminotransferase; cDNA, complementary DNA; ELISA, enzyme-linked immunosorbent assay; GTT, glucose tolerance test; H&E, hematoxylin and eosin; HFD, high-fat diet; IL, interleukin; HOMA-IR, homeostasis model assessment of insulin resistance; NTG, non-specific transgenic; IP, immunoprecipitation; ITT, insulin tolerance test; LILRB4, leukocyte immunoglobulin-like receptor B4; LILRB4-HKO, hepatocyte-specific knockout of LILRB4; LILRB4-HTG, hepatocyte-specific transgenic LILRB4; MAPK, mitogen-activated protein kinase; mRNA, messenger RNA; NAFLD, nonalcoholic fatty liver disease; NASH, nonalcoholic steatohepatitis; NC, normal chow; NEFA, nonesterified fatty acid; NF-jB, nuclear factor kappa B; PCR, polymerase chain reaction; TC, total cholesterol; TG, triglyceride; TNF-a, tumor necrosis factor a.
development of corresponding small molecules to treat this disease are urgent. As a critical pathogenesis of NAFLD, inflammation is a key driver within the process from NAFLD to NASH and other severe liver damage. (5, 6) Furthermore, inflammation is a link between hepatic lipid accumulation and insulin resistance, two other common features of NAFLD, and promotes a vicious cycle between these pathologies. (7) Thus, determining the inflammatory regulators that control NAFLD progression might be a promising strategy to treat this disease.
Leukocyte immunoglobulin-like receptor B4 (LILRB4) is an immunoreceptor primarily expressed on the membrane of immune cells, where it transduces a negative signal upon an immune response. (8) Since the discovery of LILRB4, most studies have focused on its regulation in the immune system and, in particular, its inhibitory effect on the activation of mast cells, neutrophils, and macrophages in vitro. (9) The antiinflammatory role that LILRB4 plays in vivo was established in Lilrb4 knockout mice, which show high sensitivity to proinflammatory/immune stimuli, such as immunoglobulin E, histamine, serotonin, cysteinyl leukotrienes, or prostaglandin D2. (10) Our data demonstrated that LILRB4 expression increased dramatically in hepatocytes during NAFLD progression. Given the critical role that inflammation plays in NAFLD progression, it is reasonable to hypothesize that LILRB4 plays a functional role in NAFLD development; however, this role remains unclear.
Here, using hepatocyte-specific Lilrb4 knockout (LILRB4-HKO) and transgenic (LILRB4-HTG) mice, we observed that hepatocellular LILRB4 significantly suppresses high-fat diet (HFD)-induced insulin resistance, glucose metabolic disorder, hepatic lipid accumulation, and inflammatory responses. In-depth investigations demonstrated that LILRB4 recruits SHP1 and SHP1 directly interacts with TRAF6 to block the activation of the downstream nuclear factor kappa B (NF-jB) and mitogen-activated protein kinase (MAPK) signaling pathways, leading to the attenuation of NAFLD development and its metabolic complications.
Materials and Methods

ANIMALS AND TREATMENTS
LILRB4-HKO mice were generated using the CRISPR/Cas9 system. (11) Mice with a conditional Lilrb4 knockout allele were obtained by injecting zygotes with Cas9, sgRNAs and a donor vector containing exon1 and exon2 flanked by 2 loxP sites and 2 homology arms into pseudopregnant female mice. Two founders (nos. 18 and 35) of 85 neonate mice were identified as containing floxed exons on the same allele. To further confirm that the floxed allele was functional, we used genomic DNA for in vitro Cre/ loxP-mediated recombination. Primer pairs Lilrb4-P1 and Lilrb4-P2, Lilrb4-P3, and Lilrb4-P4 were used for detecting the deletion products and the circle product, respectively (Supporting Fig. S1B,C) . All the products were confirmed via sequencing. The no. 18 mouse was crossed with C57BL/6J female mice to generate the Lilrb4 flox/flox (LILRB4-Flox) mice, which were further mated with albumin-creatinine mice to obtain LILRB4-HKO mice.
ARTICLE INFORMATION:
LILRB4-HTG mice were generated by crossing the albumin-creatinine mice with conditional Lilrb4 transgenic mice that were obtained by microinjecting the CAG-loxP-CAT-loxP-Lilrb4 cassette into fertilized C57BL/6J embryos of female mice.
The ob/ob mice were obtained from the Model Animal Research Center of Nanjing University (Nanjing, China). To overexpress or knockdown protein in mice, Adenovirus (5 3 10 9 pfu) was injected into mice. For overexpression, AdGFP was used as controls, whereas AdshRNA was used as a control for short hairpin RNA of each genes. Mice were maintained in a standard environment with a 12-hour light/dark cycle at 22 8C 6 3 8C, and the humidity was kept at 50%-60%. All animal protocols were approved by the Animal Care and Use Committee of the Third Xiangya Hospital of Central South University.
ESTABLISHMENT OF MOUSE NAFLD MODEL
The NAFLD model was established in 8-to 10-week-old male mice (weight, [25] [26] [27] 
GLUCOSE TOLERANCE TEST AND INSULIN TOLERANCE TEST
Glucose tolerance tests (GTTs) and insulin tolerance tests (ITTs) were performed in mice at 10 and 11 weeks of the HFD or NC feeding, respectively. Briefly, mice fasted overnight and then were intraperitoneally injected with glucose at a dose of 1 g Á kg 21 for the GTT assay or with insulin at a dose of 0.75 U Á kg 21 . Blood glucose levels were examined 15, 30, 60, and 120 min after injection.
SERUM OR BLOOD METABOLIC AND INFLAMMATORY PARAMETER ANALYSIS
The fasting blood glucose levels of the mice were examined using a glucometer (One Touch Ultra Easy, Life Scan, Wayne, PA) after 6 hours of fasting, and the fasting serum insulin levels were detected by way of enzyme-linked immunosorbent assay (ELISA) (Millipore, Billerica, MA) according to the manufacturer's instructions. The triglyceride (TG), total cholesterol (TC), and nonesterified fatty acid (NEFA) levels in serum were examined using commercial kits (290-63701 for TG, 294-65801 for TC, 294-63601 for NEFA; Wako, Tokyo, Japan). 
LIVER LIPID AND ENZYME ACTIVITY ASSAYS
The TG, TC, and NEFA contents in the livers of mice were detected using commercial kits as described above. The alanine aminotransferase (ALT) and aspartate aminotransferase (AST) levels in the serum were examined using an ADVIA 2400 Chemistry System analyzer (Siemens, Tarrytown, NY) to evaluate liver function.
CELL CULTURE
HEK293T, L02 and primary-cultured hepatocytes were grown in Dulbecco's modified Eagle's medium (Gibco/Thermo) containing 10% fetal bovine serum, penicillin (100 U/mL), and streptomycin (100 lg/mL) in a 5% CO 2 /water-saturated incubator at 37 8C.
PRIMARY HEPATOCYTE ISOLATION, CULTURE, AND TREATMENT
Primary hepatocytes were isolated from 6-to 8-weekold male mice as described previously. (12) Briefly, mice were anesthetized and subjected to laparotomies along the midline to expose the portal vein. A liver perfusion medium (17701-038, Life Technologies, Carlsbad, CA, USA) and liver digest medium (17703-034, Life Technologies) were successively perfused through the portal vein, and the liver was then excised, minced, filtered, and centrifuged to obtain primary hepatocytes. Percoll solution (17-0891-01, GE Healthcare Life Sciences, Buckinghamshire, UK) was applied at a concentration of 50% to purify hepatocytes. Cell viability was assayed using the Trypan Blue exclusion method; the viability of the obtained hepatocytes was more than 95%.
To establish the in vitro NASH model, primary hepatocytes were treated using palmitate (0.4 mM) for 24 hours. Cells were infected with AdLilrb4 or AdshLilrb4 at 24 hours before the palmitate challenge to investigate the role of LILRB4 in NASH-related pathologies of hepatocytes.
HISTOLOGICAL AND IMMUNOFLUORESCENCE ANALYSES
To visualize lipid accumulation in the liver, hematoxylin and eosin (H&E) and Oil Red O staining were performed as reported previously, (12) and periodic acid-Schiff staining was applied to detect glycogen levels in liver sections. Images of the histological staining were observed and recorded using a light microscope (Olympus, Tokyo, Japan). The infiltration of inflammatory cells into the liver section was tested by immunofluorescence staining applying primary antibodies of anti-CD11b (ab75476, Abcam, Cambridge Science Park, UK), anti-F4/80 (MCA497, AbD Serotec, Kidlington, UK), anti-Anti-Myeloperoxidase (ab45977, Abcam), anti-HNF4 (ab41898, Abcam), and anti-LILRB4 (S3726, Proteintech, Rosemont, IL, USA). After incubating with primary antibody overnight at 4 8C, liver sections were incubated with secondary antibody (Thermo Fisher Scientific, Waltham, MA) for 1 hour; liver slices were washed and then mounted by DAPI-Fluoromount-G (Thermo Fisher Scientific). Immunofluorescence images were captured and recorded by a fluorescence microscope (Olympus) with DP2-BSW software (version 2.2).
QUANTITATIVE REAL-TIME POLYMERASE CHAIN REACTION AND WESTERN BLOT ANALYSES
Real-time polymerase chain reaction (PCR) and western blot analyses were conducted as described previously, with minor modifications. (13) For the real-time PCR assay, total messenger RNA (mRNA) was extracted from the livers using TRIzol reagent (15596-026, Invitrogen) and then reverse-transcribed into complementary DNA (cDNA) using a Transcriptor First Strand cDNA Synthesis Kit (04896866001, Roche, Basel, Switzerland). PCR amplification was performed with SYBR Green PCR Master Mix (04887352001, Roche), and the mRNA expression of the genes of interest was normalized to that of b-actin.
The primer pairs used in this study are listed in Supporting Table S1 .
For western blot analysis, total protein samples were isolated from livers and hepatocytes using RIPA lysis buffer (880 mL RIPA, 20mL Complete [Roche], 100 mL PhosStop [Roche]). Protein concentrations were examined using a Pierce BCA Protein Assay Kit (23225, Thermo Fisher Scientific). The obtained protein (50 lg) was separated on a 10% sodium dodecyl sulfate-polyacrylamide gel electrophoresis gel, transferred to a polyvinylidene fluoride membrane, followed by blocking with 5% milk, incubation with primary antibody overnight at 4 8C and a secondary antibody at room temperature for 1 hour. The signal was detected by applying a ChemiDoc XRS 1 System with Image Lab Software. b-actin served as a loading control. The antibodies used in the experiments are listed in the Supporting Table S2 .
PLASMID CONSTRUCTS
The full-length human LILRB4 cDNA was cloned into pcDNA3.1 vector which has a flag-tag inserted behind signal peptide (1-21 amino acid). LILRB4 mutation: 3Y-F, which turned the tyrosine in each 3 ITIM (immunoreceptor tyrosine-based inhibition motif) into phenylalanine, was obtained by three rounds of point mutant PCR of which LILRB4-pcDNA3.1 was the DNA template. SHP1 was cloned into pcDNA 3.1 vector and combined with a HA-tag in C-terminal. TRAF6 cDNA was inserted into psi vector and tagged with HA, Flag and Myc label respectively. Ubiquitin coding sequence was inserted into pcDNA5 vector. SHP1 short hairpin RNA was designed and cloned into pLKO.1 plasmid.
IMMUNOPRECIPITATION ASSAY
To examine the interaction of LILRB4 with regard to the factors of interest, the corresponding plasmids were transfected into L02 cells for 24 hours. Cells were then collected and lysed in an ice-cold immunoprecipitation (IP) buffer containing 150 mmol/L NaCl, 50 mmol/L Tris-HCl, 5 mmol/L ethylene diamine tetraacetic acid, 5% glycerol, 1% Triton X-100, and a protease inhibitor cocktail (Roche). The obtained lysates were incubated with beads conjugating the corresponding antibody (Anti-FLAG M2 Magnetic Beads, M8823, Sigma, Santa Clara, CA, USA; Pierce Anti-HA Magnetic Beads, 88836, Thermo Fisher 
IN VIVO UBIQUITINATION ASSAY
The regulation by SHP1 on TRAF6 ubiquitination was performed as previously described. (14) Briefly, after transfection with the indicated plasmids for 24 h, cells were lysed in an SDS lysis buffer followed by heating for 5 min. The supernatants were collected and diluted 10-fold with the lysis buffer. The ubiquitination of TRAF6 was detected via an IP assay and a western blot analysis.
STATISTICAL ANALYSIS
All data were analyzed using SPSS (version 19.0) and are presented as the mean 6 standard error. To examine the significant differences between groups, the data were compared using a Student t test, whereas data comparisons across more than two groups were performed using a one-way analysis of variance followed by Bonferroni's post hoc tests (assuming equal variances) or Tamhane's T2 post hoc tests (assuming unequal variances). P < 0.05 was considered statistically significant.
Results
LILRB4 DEFICIENCY IN HEPATOCYTES EXACERBATES INSULIN RESISTANCE
The expression of LILRB4 in hepatic steatosis was tested in fatty livers. LILRB4 was significantly upregulated in the livers from patients with steatosis and steatohepatitis compared with nonsteatotic donors. Hepatic steatosis mouse model was established by feeding with an HFD for 12 weeks. LILRB4 expression was examined in hepatic tissue from mice fed on HFD or normal chow. Consistent with our results in human samples, the hepatic LILRB4 in HFD-fed mice was significantly increased compared with NC-fed group. (Fig.  1A,B and Supporting Fig. S1A ). Based on these results, we hypothesized that LILRB4 is involved in the development of this disease. To prove our hypothesis, we first established a LILRB4-HKO mouse strain (Fig. 1C) . A continuous HFD for 12 weeks led to a significant increase in body weight, fasting blood glucose, and serum insulin levels and a calculated homeostasis model assessment of insulin resistance (HOMA-IR) value, which were further enhanced by LILRB4 deficiency in the liver (Fig. 1D-G) . GTTs and ITTs revealed impaired insulin sensitivity in LILRB4 knockout mice (Fig. 1H,I ).
FIG. 1. Continued
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Consistently, the activity of the insulin signaling that was reflected by the expression levels of total and phosphorylated IRS
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, and GSK3b were significantly blocked in the livers of LILRB4-HKO mice compared with those of LILRB4-Flox controls after 12 weeks of HFD feeding (Fig. 1J) . In line with the exacerbated insulin resistance, LILRB4 deletion induced a marked decrease in the glycogen contents in liver sections (Fig. 1K ) but an increase in mRNA and protein expression of gluconeogenesis-related factors PEPCK and G6Pase (Fig. 1L,M) . These data collectively indicate that deficiency of LILRB4 in the liver aggravated HFDinduced obesity and insulin resistance.
HEPATOCYTE LILRB4 DEFICIENCY PROMOTES HEPATIC STEATOSIS
We next tested the functional role that LILRB4 plays in hepatic steatosis, the most prominent characteristic of NAFLD development. We found that the HFD-induced increase in liver weight and the ratio of liver weight to body weight were more significant in LILRB4-HKO mice than their LILRB4-Flox littermates ( Fig. 2A-C) . The H&E and Oil Red O staining analyses revealed an exacerbation in hepatic lipid accumulation caused by LILRB4 deficiency (Fig. 2D) , which was further confirmed by the higher TG, TC, and NEFA contents in the livers of LILRB4-HKO mice compared with those in the Flox controls (Fig.  2E) . Along with hepatic steatosis, an obvious liver dysfunction was elicited by HFD feeding as evidenced by the increased ALT, AST, and ALP levels in the serum compared with those in the NC-fed mice; this increase was enlarged by hepatocyte LILRB4 ablation (Fig.  2F) . Studies of fatty acid metabolism-related genes showed that LILRB4 deficiency significantly increases cholesterol synthesis, fatty acid uptake, and fatty acid synthesis while blocking cholesterol efflux and fatty acid oxidation (Fig. 2G) . Together, these observations demonstrate that hepatocyte LILRB4 deficiency promotes diet-induced hepatic steatosis.
HEPATOCYTE LILRB4 INHIBITS HFD-INDUCED INSULIN RESISTANCE AND HEPATIC STEATOSIS
To further evaluate the LILRB4 regulation of NAFLD progression, we generated LILRB4-HTG mice (Supporting Fig. S2A ) and fed them an HFD for 12 weeks. In contrast to the exacerbated effect of LILRB4 deficiency on insulin resistance, LILRB4 overexpression in hepatocytes inhibited the HFDinduced increases in fasting blood glucose, fasting insulin level, and the corresponding HOMA-IR value, without a significant influence on body weight (Fig.  3A-D) . The glucose levels of LILRB4-HTG mice were also lower than those of non-specific transgenic (NTG) controls in the GTT and AUC assays (Fig.  3E-F) . We also found that the glycogen content was increased by LILRB4 up-regulation, whereas the expression of PEPCK and G6Pase was lowered in the livers of LILRB4-HTG mice compared with that of the NTG group (Supporting Fig. S2B-D) . Consistently, the activation of insulin signaling was significantly elevated by LILRB4 overexpression compared with that of the littermate NTG controls (Fig. 3G) . Regarding liver pathologies, LILRB4 up-regulation markedly inhibited liver weight, ratio of liver weight to body weight, and lipid accumulation; decreased serum levels of ALT, AST and ALP; and maintained homeostasis of fatty acid metabolic profile in LILRB4-HTG mice compared with NTG controls (Fig. 3H-K and Supporting Fig. S2E) . Collectively, the data from the LILRB4-HTG and LILRB4-HKO mice demonstrated a potent inhibitory effect of hepatocyte LILRB4 on HFD-induced insulin resistance and hepatic steatosis.
HEPATOCYTE LILRB4 AMELIORATES HFD-INDUCED INFLAMMATION
Inflammation has been recognized as a pivotal driver of NAFLD development, and it possesses a critical capacity to promote insulin resistance and hepatic lipid accumulation. Here, we found that LILRB4 deficiency in hepatocytes significantly increased the expression levels of proinflammatory mediators (i.e., IL-1b, IL-6, TNF-aa and MCP-1) but decreased the antiinflammatory factor IL-10 in both the serum and the liver; the opposite phenotype was observed in LILRB4-HTG mice compared with their corresponding controls (Fig. 4A-D) . Correspondingly, the ratio of infiltrated CD11b, F4/80 and MPO-positive cells into the liver sections were greatly exacerbated by LILRB4 ablation in hepatocytes, whereas LILRB4 overexpression inhibited inflammatory cell recruitment in the liver compared to their control mice ( Fig. 4E and Supporting Fig. S3 ). In line with these results, the activity of NF-jB signaling was greatly affected by hepatocyte LILRB4. After being fed an HFD for 12 weeks, phosphorylated IKKb and IjBa in liver tissue in LILRB4-HKO mice were significantly higher than in control groups. In addition, LILRB4-HTG mice presented an opposite phenotype (Fig. 4F) . The inhibitory effect of LILRB4 on NF-jB signaling activity was further confirmed in palmitate-stimulated primary hepatocytes (Fig. 4G ). These data indicate that LILRB4 blocks inflammatory responses during HFDinduced NAFLD development.
SHP1 MEDIATES THE INHIBITORY EFFECT OF LILRB4 ON TRAF6 UBIQUITINATION
The robust effect of LILRB4 to attenuate NAFLD development encouraged us to further investigate the underlying mechanisms of LILRB4 function. Consistent with previous reports, (15) we observed a direct interaction between LILRB4 and SHP1, a tyrosine phosphatase that negatively regulates inflammatory responses (Fig. 5A) . When the three tyrosine (Y) sites in the ITIM domain of LILRB4 were mutated to phenylalanine (F), the interaction between LILRB4 and SHP1 was abolished (Fig. 5B) , suggesting that the phosphorylation of LILRB4 is required for its binding to SHP1. To further examine the downstream factors of LILRB4-SHP1, we screened potential candidates at the levels of the receptors, adaptors, and kinases that are closely involved in NAFLD progression by regulating inflammation and insulin resistance. Among these tested factors, only TRAF6 strongly bound to SHP1 (Fig. 5C) ; this finding was further validated in an IP analysis (Fig. 5D) . In response to palmitate challenge, the binding of TRAF6 to SHP1 significantly increased; the SHP1-TRAF6 interaction was enhanced by the LILRB4 dependent on its phosphorylation (Fig. 5E) .
Because ubiquitination of TRAF6 is required for its activation, we next determined whether LILRB4 and SHP1 influence TRAF6 ubiquitination. The results showed that SHP1 overexpression greatly diminished the ubiquitination level of TRAF6 in a dosedependent manner in L02 cells (Fig. 5F ). LILRB4 also markedly inhibited the ubiquitination of TRAF6; however, this effect was only exerted when the phosphorylation sites of LILRB4 were reserved in the presence of SHP1 (Fig. 5G,H) .
Consistent with the reduced ubiquitination of TRAF6 caused by LILRB4, the phosphorylated expression of TRAF6 downstream factors including TAK1, JNK1/2, IKKb, and IjBa were significantly decreased by LILRB4 overexpression (Fig. 6A) . By down-regulating SHP1 in LILRB4-overexpressed hepatocytes, we found that SHP1 knockdown reversed the inhibitory effect of LILRB4 on the activation of TRAF6 downstream signaling in palmitate-challenged cells (Fig. 6A) . To illustrate the upstream and downstream relations between LILRB4 and SHP1/TRAF6, adenovirus containing short hairpin sequence of SHP1 or short hairpin RNA control was injected into NTG and HTG mice, and AdshTRAF6 was injected into Flox and HKO mice. After feeding with an HFD for 12 weeks, the downstream signal pathways of TRAF6
were examined using western blot analysis. The results showed that LILRB4 deficiency cannot promote an NF-jB and MAPK signal while lacking Shp1. Meanwhile, when TRAF6 was knocked down, LILRB4 overexpression did not exhibit an inhibitory role in NF-jB and MAPK pathway regulation. These results suggest that LILRB4 exerts its function in an SHP1-and TRAF6-dependent manner (Fig. 6B ). Oil Red O staining revealed that reducing SHP1 disrupted the amelioration of lipid accumulation by way of LILRB4 in hepatocytes (Fig. 6C) . Furthermore, quantitative PCR assay demonstrated that LILRB4 exerted its effect on the fatty acid metabolic homeostasis and inflammation dependent on SHP1 (Fig. 6D,E) . Thus, LILRB4 interacts directly with SHP1 to inhibit TRAF6 ubiquitination and activation in which the phosphorylation of LILBR4 is required.
LILRB4 ATTENUATES NAFLD DEVELOPMENT IN ob/ob MICE
Based on the potent inhibitory effect of LILRB4 on NAFLD development, we explored the therapeutic potential of LILRB4 on this disease within ob/ob mice, a genetically induced NAFLD model. LILRB4 was overexpressed in the livers of ob/ob mice by injecting AdLILRB4, whereas mice injected with AdGFP served as controls (Fig. 7A) . After 4 weeks of AdLILRB4 injection, the levels of fasting blood glucose, fasting insulin, and HOMA-IR were significantly decreased compared with the levels in the AdGFP control group, whereas LILRB4 did not significantly change body weight (Fig. 7B-E) . Furthermore, LILRB4 improved the insulin sensitivity and glucose metabolic homeostasis of ob/ob mice (Fig.  7F,G) . Regarding liver pathologies, hepatic steatosis and inflammation were both greatly inhibited by LILRB4 overexpression (Fig. 7H-L) . The relief of hepatic steatosis and related metabolic disorders by way of AdLILRB4 suggests the potential application of LILRB4 for NAFLD treatment.
Discussion
As one of the most prevalent liver diseases worldwide, NAFLD is a progressive, pathological condition that promotes more severe liver and metabolic diseases. No therapy is available, with the exception of preventative lifestyle improvements and physical exercise. (16) In the current study, LILRB4 has been found to be upregulated in livers from NAFLD patients as well as hepatic steatosis mouse models. NAFLD is always accompanied by inflammation, (17) and LILRB4 is upregulated under inflammatory stress. (18) This phenomenon may be due to the negative feedback regulation to make LILRB4 suppress the excessive inflammation. Here, we demonstrated that an immune regulator, LILRB4, is a key suppressor of NAFLD through its potent inhibition of insulin resistance, hepatic steatosis, and inflammatory responses dependent on the SHP1-TRAF6 cascades. Importantly, adenovirusmediated overexpression of LILRB4 significantly relieved NAFLD development in a murine (ob/ob mouse) model of this disease. From a clinical perspective, these data indicate that targeting LILRB4 might be a promising therapeutic strategy for treating NAFLD and its related metabolic disorders.
In the progression of NAFLD development, the aberrant regulation of inflammation is a prominent driver. (19) While holding a robust capacity to induce insulin resistance through its functional inhibition of 
